Aurobindo Pharma Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹857
- Today's High:
- ₹886
- Open Price:
- ₹870
- 52W Low:
- ₹394.8169
- 52W High:
- ₹887.2
- Prev. Close:
- ₹867.8
- Volume:
- 2376019
Company Statistics
- Market Cap.:
- ₹486.33 billion
- Book Value:
- 458.066
- Revenue TTM:
- ₹254.70 billion
- Operating Margin TTM:
- 10.57%
- Gross Profit TTM:
- ₹135.62 billion
- Profit Margin:
- 7.76%
- Return on Assets TTM:
- 4.32%
- Return on Equity TTM:
- 7.5%
Company Profile
Aurobindo Pharma Limited had its IPO on under the ticker symbol AUROPHARMA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aurobindo Pharma Limited has a staff strength of 23,451 employees.
Stock update
Shares of Aurobindo Pharma Limited opened at ₹870 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹857 - ₹886, and closed at ₹871.2.
This is a +0.39% increase from the previous day's closing price.
A total volume of 2,376,019 shares were traded at the close of the day’s session.
In the last one week, shares of Aurobindo Pharma Limited have increased by +6.3%.
Aurobindo Pharma Limited's Key Ratios
Aurobindo Pharma Limited has a market cap of ₹486.33 billion, indicating a price to book ratio of 1.0419 and a price to sales ratio of 1.1253.
In the last 12-months Aurobindo Pharma Limited’s revenue was ₹254.70 billion with a gross profit of ₹135.62 billion and an EBITDA of ₹38.43 billion. The EBITDA ratio measures Aurobindo Pharma Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aurobindo Pharma Limited’s operating margin was 10.57% while its return on assets stood at 4.32% with a return of equity of 7.5%.
In Q2, Aurobindo Pharma Limited’s quarterly earnings growth was a positive 9.7% while revenue growth was a positive 9.9%.
Aurobindo Pharma Limited’s PE and PEG Ratio
- Forward PE
- 8.3612
- Trailing PE
- 24.5853
- PEG
Its diluted EPS in the last 12-months stands at ₹33.76 per share while it has a forward price to earnings multiple of 8.3612 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aurobindo Pharma Limited’s profitability.
Aurobindo Pharma Limited stock is trading at a EV to sales ratio of 1.0344 and a EV to EBITDA ratio of 6.4793. Its price to sales ratio in the trailing 12-months stood at 1.1253.
Aurobindo Pharma Limited stock pays annual dividends of ₹3 per share, indicating a yield of 1.09% and a payout ratio of 8.89%.
Balance sheet and cash flow metrics
- Total Assets
- ₹398.90 billion
- Total Liabilities
- ₹114.94 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 8.89%
Aurobindo Pharma Limited ended 2024 with ₹398.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹398.90 billion while shareholder equity stood at ₹268.40 billion.
Aurobindo Pharma Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹114.94 billion in other current liabilities, in common stock, ₹240.13 billion in retained earnings and ₹5.96 billion in goodwill. Its cash balance stood at ₹43.96 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹6.19 billion.
Aurobindo Pharma Limited’s total current assets stands at ₹215.46 billion while long-term investments were ₹0 and short-term investments were ₹21.29 billion. Its net receivables were ₹44.66 billion compared to accounts payable of ₹38.71 billion and inventory worth ₹85.11 billion.
In 2024, Aurobindo Pharma Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Aurobindo Pharma Limited paid ₹0.09 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹871.2
- 52-Week High
- ₹887.2
- 52-Week Low
- ₹394.8169
- Analyst Target Price
- ₹
Aurobindo Pharma Limited stock is currently trading at ₹871.2 per share. It touched a 52-week high of ₹887.2 and a 52-week low of ₹887.2. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹814.99 and 200-day moving average was ₹596.81 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5198.4% of the company’s stock are held by insiders while 2614.5% are held by institutions.
Frequently Asked Questions About Aurobindo Pharma Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin’s, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.